Syndax Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	116.81	154.08	295.39	74.36	221.97	115.24
Short-Term Investments	337.37	428.83	282.19	410.04	224.87	182.51
Cash & Short-Term Investments	454.17	582.91	577.58	484.4	446.83	297.75
Cash Growth	11.76%	0.92%	19.24%	8.41%	50.07%	387.54%
Accounts Receivable	25.4	7.6	-	-	-	-
Other Receivables	17.66	6.27	1.23	4.06	0.43	0.2
Receivables	43.07	13.87	1.23	4.06	0.43	0.2
Inventory	27.51	0.37	-	-	-	0.06
Prepaid Expenses	4.11	5.3	2	1.22	0.87	0.43
Restricted Cash	-	-	-	-	0.12	0.12
Other Current Assets	0.97	0.61	0.06	0.12	0.15	0.32
Total Current Assets	529.83	603.06	580.88	489.79	448.4	298.86
Property, Plant & Equipment	1.6	2.02	1.5	1.06	1.26	0.48
Long-Term Investments	20.15	119.52	29.83	5.47	-	-
Other Long-Term Assets	0.22	0.22	0.68	0.92	-	1.27
Total Assets	551.79	724.82	612.88	497.24	449.66	300.61
Accounts Payable	13.83	11.63	9.96	4.35	5.67	3.51
Accrued Expenses	76.51	59.68	38.97	23.67	12.76	11.25
Current Portion of Long-Term Debt	22.93	12.12	-	-	-	2.29
Current Portion of Leases	0.33	0.48	1.05	0.44	0.36	0.32
Current Unearned Revenue	-	-	-	-	-	1.52
Other Current Liabilities	0.6	19.65	8.12	0.6	1.89	-
Total Current Liabilities	114.19	103.55	58.1	29.07	20.68	18.87
Long-Term Debt	320.99	331.57	-	-	19.9	17.83
Long-Term Leases	1.19	1.58	0.59	0.72	0.71	0.1
Long-Term Unearned Revenue	-	-	-	-	-	11.62
Other Long-Term Liabilities	-	-	-	-	-	0
Total Liabilities	436.36	436.69	58.68	29.79	41.29	48.43
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,553	1,509	1,456	1,161	952.02	820.82
Retained Earnings	-1,439	-1,221	-902.4	-693.04	-543.7	-568.63
Comprehensive Income & Other	0.53	0.16	0.22	-0.81	0.05	-0
Total Common Equity	115.43	288.12	554.2	467.45	408.37	252.19
Shareholders' Equity	115.43	288.12	554.2	467.45	408.37	252.19
Total Liabilities & Equity	551.79	724.82	612.88	497.24	449.66	300.61
Total Debt	345.43	345.74	1.64	1.16	20.97	20.54
Net Cash (Debt)	108.74	237.17	575.95	483.24	425.86	277.21
Net Cash Growth	-73.19%	-58.82%	19.19%	13.47%	53.62%	360.68%
Net Cash Per Share	1.26	2.77	8.18	7.95	7.94	6.71
Filing Date Shares Outstanding	86.91	86.02	84.97	68.44	55.01	48.24
Total Common Shares Outstanding	86.91	85.69	84.83	68.11	54.98	47.88
Working Capital	415.64	499.51	522.78	460.72	427.71	279.99
Book Value Per Share	1.33	3.36	6.53	6.86	7.43	5.27
Tangible Book Value	115.43	288.12	554.2	467.45	408.37	252.19
Tangible Book Value Per Share	1.33	3.36	6.53	6.86	7.43	5.27
Machinery	-	0.25	0.25	0.25	0.54	0.41
Leasehold Improvements	-	0.17	0.17	0.17	0.17	0.17

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q